67 related articles for article (PubMed ID: 17554150)
1. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury.
Menne J; Park JK; Shushakova N; Mengel M; Meier M; Fliser D
J Am Soc Nephrol; 2007 Jul; 18(7):2046-53. PubMed ID: 17554150
[TBL] [Abstract][Full Text] [Related]
2. Chronic erythropoietin treatment affects different molecular pathways of diabetic cardiomyopathy in mouse.
Shushakova N; Park JK; Menne J; Fliser D
Eur J Clin Invest; 2009 Sep; 39(9):755-60. PubMed ID: 19614950
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin prevents diabetes-induced podocyte damage.
Schiffer M; Park JK; Tossidou I; Bartels J; Shushakova N; Menne J; Fliser D
Kidney Blood Press Res; 2008; 31(6):411-5. PubMed ID: 19096223
[TBL] [Abstract][Full Text] [Related]
5. The effect of low-dose Continuous Erythropoietin receptor activator in an experimental model of acute Cyclosporine A induced renal injury.
Meerwein C; Korom S; Arni S; Inci I; Weder W; Jungraithmayr W
Eur J Pharmacol; 2011 Dec; 671(1-3):113-9. PubMed ID: 21968143
[TBL] [Abstract][Full Text] [Related]
6. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.
Kosugi T; Nakayama T; Li Q; Chiodo VA; Zhang L; Campbell-Thompson M; Grant M; Croker BP; Nakagawa T
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F609-16. PubMed ID: 20015944
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
[TBL] [Abstract][Full Text] [Related]
8. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.
Ye M; Wysocki J; William J; Soler MJ; Cokic I; Batlle D
J Am Soc Nephrol; 2006 Nov; 17(11):3067-75. PubMed ID: 17021266
[TBL] [Abstract][Full Text] [Related]
9. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy.
Ninichuk V; Kulkarni O; Clauss S; Anders H-
Eur J Med Res; 2007 Aug; 12(8):351-5. PubMed ID: 17933712
[TBL] [Abstract][Full Text] [Related]
10. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Sung SH; Ziyadeh FN; Wang A; Pyagay PE; Kanwar YS; Chen S
J Am Soc Nephrol; 2006 Nov; 17(11):3093-104. PubMed ID: 16988063
[TBL] [Abstract][Full Text] [Related]
11. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome.
Aizawa K; Takeda S; Tashiro Y; Yorozu K; Hirata M; Kanada H; Moriguchi Y; Endo K
Am J Nephrol; 2012; 36(5):419-26. PubMed ID: 23128049
[TBL] [Abstract][Full Text] [Related]
12. CERA Attenuates Kidney Fibrogenesis in the db/db Mouse by Influencing the Renal Myofibroblast Generation.
Fischer C; Deininger N; Wolf G; Loeffler I
J Clin Med; 2018 Jan; 7(2):. PubMed ID: 29385703
[TBL] [Abstract][Full Text] [Related]
13. Association between endothelin-1 and collagen deposition in db/db diabetic mouse kidneys.
Mishra R; Emancipator SN; Kern TS; Simonson MS
Biochem Biophys Res Commun; 2006 Jan; 339(1):65-70. PubMed ID: 16297859
[TBL] [Abstract][Full Text] [Related]
14. Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice.
Peters V; Schmitt CP; Zschocke J; Gross ML; Brismar K; Forsberg E
Amino Acids; 2012 Jun; 42(6):2411-6. PubMed ID: 21833769
[TBL] [Abstract][Full Text] [Related]
15. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
Hamada Y; Fukagawa M
Kobe J Med Sci; 2007; 53(1-2):53-61. PubMed ID: 17582205
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin protects critically perfused flap tissue.
Rezaeian F; Wettstein R; Amon M; Scheuer C; Schramm R; Menger MD; Pittet B; Harder Y
Ann Surg; 2008 Dec; 248(6):919-29. PubMed ID: 19092336
[TBL] [Abstract][Full Text] [Related]
17. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.
Mima A; Arai H; Matsubara T; Abe H; Nagai K; Tamura Y; Torikoshi K; Araki M; Kanamori H; Takahashi T; Tominaga T; Matsuura M; Iehara N; Fukatsu A; Kita T; Doi T
Diabetes; 2008 Jun; 57(6):1712-22. PubMed ID: 18285555
[TBL] [Abstract][Full Text] [Related]
18. Effects of continuous erythropoietin receptor activator (CERA) in kidney transplant recipients.
Esposito C; Abelli M; Sileno G; Migotto C; Torreggiani M; Serpieri N; Maggi N; Esposito V; Grosjean F; Scaramuzzi ML; Montagna F; Canton AD
Transplant Proc; 2012 Sep; 44(7):1916-7. PubMed ID: 22974870
[TBL] [Abstract][Full Text] [Related]
19. Halofuginone prevents extracellular matrix deposition in diabetic nephropathy.
Sato S; Kawamura H; Takemoto M; Maezawa Y; Fujimoto M; Shimoyama T; Koshizaka M; Tsurutani Y; Watanabe A; Ueda S; Halevi K; Saito Y; Yokote K
Biochem Biophys Res Commun; 2009 Feb; 379(2):411-6. PubMed ID: 19114027
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis.
Sakai T; Nambu T; Katoh M; Uehara S; Fukuroda T; Nishikibe M
Biochem Biophys Res Commun; 2009 Jun; 384(2):173-9. PubMed ID: 19401193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
